Assertio Therapeutics Inc

Assertio Holdings Inc. a commercial pharmaceutical company provides medicines in the areas of neurology rheumatology and pain and inflammation. Its pharmaceutical products include INDOCIN an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain nausea photophobia and phonophobia; Zipsor a NSAID for relief of mild to moderate pain in adults; SPRIX a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe active rheumatoid arthritis and active polyarticular juvenile idiopathic arthritis as well as treat adult with severe recalcitrant and disabling psoriasis. The company was formerly known as Assertio Therapeutics Inc. and changed its name to Assertio Holdings Inc. in May 2020. Assertio Holdings Inc. was incorporated in 1995 and is headquartered in Lake Forest Illinois.